Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Observational, Prospective Study to Assess the Safety Profile of Rituximab in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (B-CLL)

NCT01224093 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01224093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01224093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Observational, Prospective Study to Assess the Safety Profile of Rituximab in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (B-CLL)
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
October 31, 2010
Completion date
February 28, 2014
Enrollment
219 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia, chronic